MA07.07 Validation Analysis of MET IHC as a Biomarker for Amivantamab-Lazertinib Response in Post-Osimertinib EGFR-Mutated NSCLC
Benjamin Besse(Université Paris-Saclay), P. Tomasini(Aix-Marseille Université), B.C. Cho(Yonsei University), Y. Wang(Sichuan University), D.-W. Kim(Seoul National University Hospital), Chun‐Ting Lin(National University of Tainan), Christina S. Baik(Fred Hutch Cancer Center), S.-H. Lee(Samsung Medical Center), Shun Lu(Shanghai Jiao Tong University), L. Paz-Ares(Hospital Universitario 12 De Octubre), R.E. Sanborn(Providence Portland Medical Center), Jie Yang(National Taiwan University), M. D’Arcangelo(Ospedale "Santa Maria delle Croci" di Ravenna), Marcia Cruz–Correa(University of Puerto Rico System), Sebastian Michels(University Hospital Cologne), J.C. Curtin(Johnson & Johnson (United States)), Xiaohui Luo(Johnson & Johnson (United Kingdom)), Zacharias Anastasiou(Johnson & Johnson (United States)), Isabelle Leconte(Johnson & Johnson (United States)), Zhuang Jiang(Johnson & Johnson (United States)), Leonardo Trani(Johnson & Johnson (United States)), Mahadi Baig(Johnson & Johnson (United States)), E. Felip(Hebron University)
Cited by 1
Abstract
Related Papers
No related papers found
Powered by citation graph analysis